Top Story
- Integrated Evidence Assessment & Planning
ISPOR, the Professional Society for Health Economics and Outcomes Research, published its “2024-2025 Top 10 HEOR Trends Report.” In its fifth edition, this biennial report identifies key trends affecting global healthcare decision-making based on member inputs and strategic curation by its Health Science Policy Council. The [...]
Latest Stories
Featured Webinars
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches
Thursday, February 29, 2024
Sponsor: Carelon Research
Integrated Evidence Generation Planning: Driving Successful Reimbursement and Life Cycle Management
Tuesday, February 27, 2024
Sponsor: OPEN Health
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
Gamida Cell Ltd. AVTE date announcement
Aerovate Therapeutics plans to announce top-line results for their Phase 2/3 trial of AV-101 - (IMPAHCT) on June 30, 2024. As of now, the drug has a 29.6% chance of moving on.
Aerovate Therapeutics rocketed [...]
Read MoreLongeveron AVIR date announcement
Now that the Phase 3 trial of Bemnifosbuvir (AT-527) - (SUNRISE-3) is completed, Atea Pharmaceuticals will announce their top-line results on March 31, 2024. The community is currently bullish on the prospects of progression, as [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest